ALKS
Alkermes plc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
Market Cap: 9.2 Billion
Primary Exchange: Nasdaq Global Select
Website: http://www.alkermes.com
Shares Outstanding: 154 Million
Float: 152 Million
Dividend: 0.0 (0.0%)
Beta: 1.986142
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 11.6 Million
Ethical Flags
Longest drawdown: 1472 trading days
From: 2015-12-28 To: 2019-10-18
Lowest Point:
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
via: PR Newswire at 2019-06-12 03:00:00:000
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...
Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma
via: PR Newswire at 2019-06-12 03:00:00:000
-- Initiation of Monotherapy Efficacy Evaluation Follows Selection of Recommended Phase 2 Dose in Dose-Escalation Stage -- -- Proof-of-Mechanism Demonstrated by Desired Expansion of Tumor-Killing Immune Cells While Avoiding Activation of Immunosuppressive Cells -- DUBLIN , June 12… read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|